Poolbeg Pharma News & Media

Post List #1

2024

POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, PhD, MSc, BSc, Paula Maguire, PhD, Jiwon Yang, PhD, James G Keck, Laura Maher, MSc, Mark Graham, Martin F Kaiser, MD, FRCP, FRCPath, Emma Searle, MD, PhD and Mark Sumeray, MD

2023

POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

E. Searle, L.F. Tremble, R. Popat, D.T. de Bruin, M. Moerland, B. Buckley

2023

Inhibition of local and systemic inflammatory responses by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS administration in healthy volunteers

D.T. de Bruin, M.A.A. Jansen, J. Skillington, L. Tremble, S. Rajbally, N.B. Klarenbeek, M. Moerland

Publications

Post List #1

POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

Inhibition of local and systemic inflammatory responses by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS administration in healthy volunteers